Drug-adapted cancer cell lines as preclinical models of acquired resistance

Abstract

Acquired resistance formation limits the efficacy of anti-cancer therapies. Acquired and intrinsic resistance differ conceptually. Acquired resistance is the consequence of directed evolution, whereas intrinsic resistance depends on the (stochastic) presence of pre-existing resistance mechanisms. Preclinical model systems are needed to study acquired drug resistance because they enable: (1) in depth functional studies; (2) the investigation of non-standard treatments for a certain disease condition (which is necessary to identify small groups of responders); and (3) the comparison of multiple therapies in the same system. Hence, they complement data derived from clinical trials and clinical specimens, including liquid biopsies. Many groups have successfully used drug-adapted cancer cell lines to identify and elucidate clinically relevant resistance mechanisms to targeted and cytotoxic anti-cancer drugs. Hence, we argue that drug-adapted cancer cell lines represent a preclinical model system in their own right that is complementary to other preclinical model systems and clinical data.

Keywords

Cancer / acquired drug resistance / cancer cell lines / drug adaptation / cancer therapy / cancer models

References

[1] Kamat AM,Efstathiou JA,Malmström PU.Bladder cancer..Lancet2016;388:2796-810

[2] Harbeck N.Breast cancer..Lancet2017;389:1134-50

[3] Iacobucci I.Genetic Basis of Acute Lymphoblastic Leukemia..J Clin Oncol2017;35:975-83 PMCID:PMC5455679

[4] Litwin MS.The Diagnosis and Treatment of Prostate Cancer: A Review..JAMA2017;317:2532-42

[5] Herbst RS,Boshoff C.The biology and management of non-small cell lung cancer..Nature2018;553:446-54

[6] Lim SH.Optimizing therapy in advanced-stage Hodgkin lymphoma..Blood2018;131:1679-88

[7] Pierorazio PM,Black PC,Heidenreich A.Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary..Eur Urol2018;73:899-907

[8] Fenton TR,Wass MN.What really matters - response and resistance in cancer therapy..Cancer Drug Resist2018;1:200-3

[9] DeVita VT Jr.A history of cancer chemotherapy..Cancer Res2008;68:8643-53

[10] Holohan C,Longley DB.Cancer drug resistance: an evolving paradigm..Nat Rev Cancer2013;13:714-26

[11] Sachs JR,Gadamsetty S,de Alwis DP.Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example..Clin Cancer Res2016;22:1318-24

[12] Wong KM,Eckhardt SG.The changing landscape of phase I trials in oncology..Nat Rev Clin Oncol2016;13:106-17

[13] Gatzka MV.Targeted Tumor Therapy Remixed-An Update on the Use of Small-Molecule Drugs in Combination Therapies..Cancers (Basel)2018;10:pii:E155 PMCID:PMC6025289

[14] Kavanagh S,Lipton JH.Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia..Expert Opin Emerg Drugs2018;23:51-62

[15] Kleczko EK.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities..Mol Cancer2018;17:60 PMCID:PMC5817864

[16] Larionov AA.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients..Front Oncol2018;8:89 PMCID:PMC5894159

[17] Sharma GG,Mologni L,Gambacorti-Passerini C.Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes..Cancers (Basel)2018;10:pii:E62 PMCID:PMC5876637

[18] Soverini S,Bavaro L,Martinelli G.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy..Mol Cancer2018;17:49 PMCID:PMC5817796

[19] Tomasello C,Napolitano M,Grizzi G.Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives..Crit Rev Oncol Hematol2018;123:149-61

[20] Esposito C,La Porta ML,Roma C.The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies..Cancer Biol Ther2013;14:1143-6 PMCID:PMC3912037

[21] Arena S,Siravegna G,Cañadas I.Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer..Clin Cancer Res2015;21:2157-66

[22] Miklos W,Kowol CR,Dornetshuber-Fleiss R.Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance..Cancer Lett2015;361:112-20

[23] Carter L,Mesquita B,Leong HS.Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer..Nat Med2017;23:114-9

[24] Heitzer E,Roberts CES.Current and future perspectives of liquid biopsies in genomics-driven oncology..Nat Rev Genet2019;20:71-88

[25] Hayes DF.Precision Medicine and Testing for Tumor Biomarkers-Are All Tests Born Equal?.JAMA Oncol2018;4:773-4

[26] Warren JD,Bunker AM,Furtado LV.Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer..BMC Med2011;9:133 PMCID:PMC3271041

[27] Leighl NB,Biermann WA,Mino-Kenudson M.Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline..J Clin Oncol2014;32:3673-9 PMCID:PMC5321089

[28] Sacher AG,Dahlberg SE,O’Connell A.Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer..JAMA Oncol2016;2:1014-22 PMCID:PMC4982795

[29] Lee DH.Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures..Pharmacol Ther2017;174:1-21

[30] Nian J,Ming S,Ma Y.Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis..Clin Transl Gastroenterol.2017;8:e216 PMCID:PMC5288600

[31] Song L,Peng X,Li Y.The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis..Sci Rep2017;7:3032 PMCID:PMC5465203

[32] Kalemkerian GP,Kennedy EB,Donington J.Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update..J Clin Oncol2018;36:911-9

[33] Sharma SV,Settleman J.Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents..Nat Rev Cancer2010;10:241-53

[34] Gordon JL,Reynolds MM.Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer..Diseases.2018;6:pii:E85 PMCID:PMC6313784

[35] Dai X,Bai Z.Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping..J Cancer2017;8:3131-41 PMCID:PMC5665029

[36] Shoemaker RH.The NCI60 human tumour cell line anticancer drug screen..Nat Rev Cancer2006;6:813-23

[37] Goodspeed A,Gray JW.Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics..Mol Cancer Res2016;14:3-13 PMCID:PMC4828339

[38] Geraghty RJ,Davis JM,Freshney RI.Guidelines for the use of cell lines in biomedical research..Br J Cancer2014;111:1021-46 PMCID:PMC4580382

[39] Barretina J,Stransky N,Margolin AA.The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity..Nature2012;483:603-7 PMCID:PMC3320027

[40] Basu A,Cheah JH,Liu K.An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules..Cell2013;154:1151-61 PMCID:PMC3954635

[41] Yang W,Greninger P,Lightfoot H.Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells..Nucleic Acids Res2013;41:D955-61 PMCID:PMC3531057

[42] Iorio F,Vis DJ,Menden MP.A Landscape of Pharmacogenomic Interactions in Cancer..Cell2016;166:740-54 PMCID:PMC4967469

[43] Ghandi M,Jané-Valbuena J,Lo CC.Next-generation characterization of the Cancer Cell Line Encyclopedia..Nature2019;569:503-8

[44] Petljak M,Brammeld JS,Wedge DC.Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis..Cell2019;176:1282-94.e20 PMCID:PMC6424819

[45] van der Meer D,Yang W,Hall C.Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models..Nucleic Acids Res2019;47:D923-29 PMCID:PMC6324059

[46] Juliano RL.A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants..Biochim Biophys Acta1976;455:152-62

[47] Szakács G,Ludwig JA,Gottesman MM.Targeting multidrug resistance in cancer..Nat Rev Drug Discov2006;5:219-34

[48] Robey RW,Hall MD,Bates SE.Revisiting the role of ABC transporters in multidrug-resistant cancer..Nat Rev Cancer2018;18:452-64

[49] Cole SP,Gerlach JH,Grant CE.Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line..Science1992;258:1650-4

[50] Roskoski R Jr.Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers..Pharmacol Res2018;139:395-411

[51] Engelman JA,Mitsudomi T,Hyland C.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling..Science2007;316:1039-43

[52] Hata AN,Archibald HL,Siddiqui FM.Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition..Nat Med2016;22:262-9 PMCID:PMC4900892

[53] Ramirez M,Steininger RJ,Roth MA.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells..Nat Commun2016;7:10690 PMCID:PMC4762880

[54] Torres-Collado AX,Jazirehi AR.Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)..Cancers (Basel)2018;10:E157 PMCID:PMC6025215

[55] Nazarian R,Wang Q,Koya RC.Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation..Nature2010;468:973-7 PMCID:PMC3143360

[56] Poulikakos PI,Janakiraman M,Ng C.RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)..Nature2011;480:387-90 PMCID:PMC3266695

[57] Shi H,Kong X,Lee H.Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance..Nat Commun2012;3:724 PMCID:PMC3530385

[58] Bivona TG,Parker J,Taron M.FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR..Nature2011;471:523-6 PMCID:PMC3541675

[59] Crystal AS,Sequist LV,Niederst MJ.Patient-derived models of acquired resistance can identify effective drug combinations for cancer..Science2014;346:1480-6 PMCID:PMC4388482

[60] Joseph JD,Qian J,Shao G.A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509..Cancer Discov2013;3:1020-9

[61] Korpal M,Gao X,Ruddy DA.An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)..Cancer Discov2013;3:1030-43

[62] Wade M,Wahl GM.MDM2, MDMX and p53 in oncogenesis and cancer therapy..Nat Rev Cancer2013;13:83-96 PMCID:PMC4161369

[63] Cinatl J Jr,Hardcastle I.Resistance acquisition to MDM2 inhibitors..Biochem Soc Trans2014;42:752-7

[64] Tisato V,Gonelli A,Zauli G.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer..J Hematol Oncol2017;10:133 PMCID:PMC5496368

[65] Aziz MH,Maki CG.Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3..Oncogene2011;30:4678-86 PMCID:PMC3347888

[66] Michaelis M,Barth S,van Rikxoort M.Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug resistant cancer cells..Cell Death Dis2011;2:e243 PMCID:PMC3252738

[67] Jones RJ,Baladandayuthapani V,Orlowski RZ.Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA..Mol Cancer Ther2012;11:2243-53 PMCID:PMC3469746

[68] Michaelis M,Agha B,Voges Y.Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents..Cell Death Dis2012;3:e294 PMCID:PMC3358013

[69] Hoffman-Luca CG,McEachern D,Sun W.Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo..Clin Cancer Res2015;21:2558-68 PMCID:PMC4957562

[70] Drummond CJ,Liu J,Hutton C.TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation..Oncotarget2016;7:46203-18 PMCID:PMC5216791

[71] Jung J,Dickson MA,Le Cesne A.TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma..Nat Commun2016;7:12609 PMCID:PMC5013668

[72] Domingo-Domenech J,Rodriguez-Bravo V,Quinn SA.Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells..Cancer Cell2012;22:373-88 PMCID:PMC5989708

[73] Zahreddine HA,Assouline S,Romeo AA.The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation..Nature2014;511:90-3 PMCID:PMC4138053

[74] Göllner S,Agrawal-Singh S,Klein HU.Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia..Nat Med2017;23:69-78 PMCID:PMC6548550

[75] Schneider C,Baldauf HM,Thomas D.SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia..Nat Med2017;23:250-5

[76] Malani D,Yadav B,Eldfors S.Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML..Leukemia2017;31:1187-95 PMCID:PMC5420795

[77] Benedetti V,Luca Beretta G,Tinelli S.Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds..Mol Cancer Ther2008;7:679-87

[78] Cossa G,Cassinelli G,Arrighetti N.Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells..Cancer Lett2014;347:212-24

[79] McGranahan N.Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future..Cell2017;168:613-28

[80] Greaves M.Nothing in cancer makes sense except….BMC Biol2018;16:22 PMCID:PMC5822549

[81] Stanta G.Overview on Clinical Relevance of Intra-Tumor Heterogeneity..Front Med (Lausanne)2018;5:85 PMCID:PMC5897590

[82] Sequist LV,Dias-Santagata D,Turke AB.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR Inhibitors..Sci Transl Med2011;3:75ra26 PMCID:PMC3132801

[83] Jun HJ,Chi D,Zhu H.Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme..Oncogene2012;31:3039-50 PMCID:PMC3774279

[84] Basile KJ,Dadpey N,Fortina P.In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors..Cancer Res2013;73:7101-10 PMCID:PMC3851924

[85] Patel C,Varma S,Björkholm M.Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity..Cancer2013;119:3076-83 PMCID:PMC3735855

[86] Kemper K,Cornelissen-Steijger P,Weeber F.Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts..EMBO Mol Med2015;7:1104-18 PMCID:PMC4568946

[87] Soucheray M,Pulido I,Paweletz CP.Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition..Cancer Res2015;75:4372-83 PMCID:PMC4548796

[88] Quéré G,Robinet G,Raguenes O.Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer..BMC Cancer2016;16:210 PMCID:PMC4788951

[89] Litzenburger UM,Wu B,Sheffield NC.Single-cell epigenomic variability reveals functional cancer heterogeneity..Genome Biol2017;18:15 PMCID:PMC5259890

[90] Levina V,DeMarco R,Lokshin AE.Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties..PLoS One2008;3:e3077 PMCID:PMC2518121

[91] Aziz MH,Maki CG.Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3..Oncogene2011;30:4678-86 PMCID:PMC3347888

[92] Little AS,Sale MJ,Dry JR.Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells..Sci Signal2011;4:ra17

[93] Hata AN,Archibald HL,Siddiqui FM.Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition..Nat Med2016;22:262-9 PMCID:PMC4900892

[94] Brady SW,Qiao Y,Shrestha G.Combating subclonal evolution of resistant cancer phenotypes..Nat Commun2017;8:1231 PMCID:PMC5666005

[95] Hata AN,Archibald HL,Siddiqui FM.Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers..Oncogene2017;36:6581-91 PMCID:PMC5700857

[96] Kim C,Sei E,Hartman J.Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing..Cell2018;173:879-893.e13 PMCID:PMC6132060

[97] Liu Y,Ou Q,Wang X.Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib..Lung Cancer2018;118:1-5

[98] Quek L,Kennedy A,Amatangelo M.Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib..Nat Med2018;24:1167-77

[99] Schulte M,Rahmann S.Cancer evolution, mutations, and clonal selection in relapse neuroblastoma..Cell Tissue Res2018;372:263-8

[100] Nayar U,Kapstad C,Waks AG.Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies..Nat Genet2019;51:207-16

[101] Sanchez-Vega F,Castel P,Tuvy Y.EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer..Cancer Discov2019;9:199-209 PMCID:PMC6368868 [Available on 2020-02-01]

[102] Michaelis M,Rothweiler F,Mernberger M.TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance..biorXiv.2018;

[103] Su Y,Robert L,Tsoi J.Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance..Proc Natl Acad Sci U S A2017;114:13679-84 PMCID:PMC5748184

[104] Sharma A,Kumar V,Leong HS.Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy..Nat Commun2018;9:4931 PMCID:PMC6250721

[105] Behrens D,Fichtner I.Pancreatic cancer models for translational research..Pharmacol Ther2017;173:146-58

[106] Fichtner I,Behrens D,Rolff J.Animal models for personalized treatment options..Int J Clin Pharmacol Ther2017;55:698-700

[107] Kodack DP,Dastur A,Dardaei L.Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care..Cell Rep2017;21:3298-309 PMCID:PMC5745232

[108] Lampreht Tratar U,Cemazar M.Transgenic Mouse Models in Cancer Research..Front Oncol2018;8:268 PMCID:PMC6062593

[109] Tellez-Gabriel M,Cadé M,Heymann MF.Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine..Cancers (Basel)2018;11:pii: E19 PMCID:PMC6356998

[110] Xu H,Yi M,Song Y.Organoid technology and applications in cancer research..J Hematol Oncol2018;11:116 PMCID:PMC6139148

[111] Koga Y.Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors..Cells2019;8:pii: E418 PMCID:PMC6562882

[112] Ramamoorthy P,Kaushik G,Chastain KM.Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response..Cancer Res2019;79:1681-95 PMCID:PMC6445669

[113] Smith RC.Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids..Cell Stem Cell2019;24:12-24 PMCID:PMC6516073 [Available on 2020-01-03]

[114] Sontheimer-Phelps A,Ingber DE.Modelling cancer in microfluidic human organs-on-chips..Nat Rev Cancer2019;19:65-81

[115] Naundorf H,Lykkesfeldt AE,Neumann C.Development and characterization of a tamoxifen-resistant breast carcinoma xenograft..Br J Cancer2000;82:1844-50 PMCID:PMC2363223

[116] Zhang Z,Lin L,Au V.Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer..Nat Genet2012;44:852-60 PMCID:PMC3408577

[117] Cottu P,Assayag F,Chateau-Joubert S.Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts..Clin Cancer Res2014;20:4314-25

[118] Kopp F,Oak PS,Herrmann A.Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells..Transl Oncol2014;7:702-11 PMCID:PMC4311025

[119] Pirazzoli V,Song X,Walther Z.Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1..Cell Rep2014;7:999-1008 PMCID:PMC4074596

[120] Pyo KH,Kim HR,Yun MR.Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer..J Thorac Oncol2017;12:491-500

[121] Xue Y,Baslan T,Solomon M.An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer..Nat Med2017;23:929-37 PMCID:PMC5696266

[122] Buzzelli JN,Brown G,Muschel RJ.Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance..Stem Cell Res2018;27:109-20 PMCID:PMC5842239

[123] Esteve-Arenys A,Chamorro-Jorganes A,Rodriguez V.The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma..Oncogene2018;37:1830-44

[124] Lau WM,Huang KK,Das K.Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β..Mol Cancer Ther2018;17:232-42

[125] Yun MR,Kim SK,Pyo KH.Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors..Cancer Res2018;78:3350-62